SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-21-008915
Filing Date
2021-08-24
Accepted
2021-08-24 17:06:52
Documents
13
Period of Report
2021-08-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_082021.htm   iXBRL 8-K 36975
2 PRESS RELEASE ex99-1.htm EX-99.1 13286
  Complete submission text file 0001387131-21-008915.txt   232306

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20210820.xsd EX-101.SCH 3063
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20210820_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20210820_pre.xml EX-101.PRE 22384
6 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_082021_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 211202876
SIC: 2834 Pharmaceutical Preparations